GlassScriptPhysician profile
Tracy L Nelson
NPI 1346499738
$24,479.83
in general payments reported to CMS, 2019-2025
24 companies · $1,792 in 2025
The $1,792 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $5,124 · 2023: $2,851 · 2024: $2,725 · 2025: $1,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,156 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,533 · Education: $643 · Travel and Lodging: $35.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,156.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,533.00 |
| Education | $643.34 |
| Travel and Lodging | $35.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $14,579.17 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Ucb, INC. | $4,405.50 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,381.78 | 2021-2025 | |
| Genzyme Corporation | $698.48 | 2021-2025 | |
| Janssen Biotech, INC. | $661.41 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Arcutis Biotherapeutics, INC. | $430.82 | 2023-2024 | Zoryve |
| Sanofi-Aventis U.S. LLC | $360.69 | 2021-2025 | |
| Incyte Corporation | $347.33 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $342.71 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $281.26 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $228.89 | 2021-2025 | |
| Amgen INC. | $169.38 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $139.78 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $101.75 | 2022 | |
| Leo Pharma INC. | $72.33 | 2022-2025 | Adbry |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $53.69 | 2024-2025 | Nemluvio, Aklief |
| Mayne Pharma Commercial LLC | $52.14 | 2024-2025 | |
| Organon LLC | $45.49 | 2025 | |
| Biosense Webster, INC. | $36.29 | 2025 | Qdot Micro |
| Biofrontera INC. | $23.79 | 2021 | |
| Fresenius Kabi USA, LLC | $18.50 | 2023 | Idacio |
| Regeneron Healthcare Solutions, INC. | $17.64 | 2024 | Dupixent |
| Dermavant Sciences, INC. | $17.14 | 2024 | Vtama |
| Botanix Sb INC | $13.87 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.